Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Findings from A. Svensson and co-authors broaden understanding of angiogenesis
March 25th, 2008
"High risk neuroblastoma (NB) patients have an overall five-year survival of similar to 50%, indicating the need for new treatment strategies, such as angiogenesis inhibition. The angiogenesis inhibitor TNP-470 (30 mg/kg, every other day, subcutaneously) was given to nude mice with subcutaneous human neuroblastoma xenografts," scientists writing in the journal Anticancer Research report. "The plasma concentrations of the angiogenesis stimulators, i.e. vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2) and hepatocyte growth factor (HGF), were assayed longitudinally. Angiogenesis, proliferation and apoptosis were quantified on tumor...
Source: Cancer Weekly (2008-03-25)
|
